Alliance for Multispecialty Research, LLC | AMR Knoxville, TN
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Prior systemic therapy, diagnoses and disease setting as follows:
For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy and one of the following,
For Part 2 (dose expansion), IO treatment -naïve, e.g., no prior receipt of an anti PD-1, anti-PD-L1 or PD-L1, anti-CTLA-4, GITR, LAG3, TIM3, OX-40, IL-2, 4-1BB or other immune modulator, and have not received prior systemic therapy and one of the following,
ECOG performance score of 0 or 1.
Life expectancy > 3 months, in the opinion of the investigator.
Histologically confirmed solid tumors with measurable disease per RECIST v1.1.
Willingness to avoid pregnancy or fathering children.
Exclusion criteria
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
8 participants in 2 patient groups
Loading...
Central trial contact
Incyte Corporation Call Center (US); Incyte Corporation Call Center (ex-US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal